|
JPS509164B1
(cg-RX-API-DMAC7.html)
|
1970-12-29 |
1975-04-10 |
|
|
|
DK159770C
(da)
|
1979-06-29 |
1991-04-22 |
Wellcome Found |
Analogifremgangsmaade til fremstilling af etherforbindelser eller farmakologisk acceptable salte deraf, samt ether-mellemprodukter til anvendelse som udgangsforbindelser ved fremgangsmaaden
|
|
IL64573A
(en)
|
1980-12-18 |
1985-04-30 |
Wellcome Found |
Derivatives of formylphenoxyalkanoic acids and formylphenoxymethylbenzoic acids,their preparation and pharmaceutical formulations containing them
|
|
JPS58167304A
(ja)
|
1982-03-24 |
1983-10-03 |
松下電器産業株式会社 |
ごみ処理装置
|
|
AU576322B2
(en)
|
1983-07-22 |
1988-08-25 |
Ici Australia Limited |
Alpha-substituted-alpha-cyanomethyl alcohols
|
|
US4783443A
(en)
|
1986-03-03 |
1988-11-08 |
The University Of Chicago |
Amino acyl cephalosporin derivatives
|
|
JPH05255106A
(ja)
|
1990-10-31 |
1993-10-05 |
Toray Ind Inc |
血小板減少症治療剤
|
|
JPH059164A
(ja)
|
1991-07-02 |
1993-01-19 |
Sumitomo Chem Co Ltd |
光学活性マンデロニトリル誘導体の製造方法
|
|
GB9217331D0
(en)
|
1992-08-14 |
1992-09-30 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US5872151A
(en)
|
1992-10-01 |
1999-02-16 |
Glaxo Wellcome Inc. |
Immunopotentiatory agents and physiologically acceptable salts thereof
|
|
US6096786A
(en)
|
1992-10-01 |
2000-08-01 |
Glaxo Wellcome Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
ATE146075T1
(de)
|
1992-10-01 |
1996-12-15 |
Wellcome Found |
Tucaresol als mittel zur immunopotentierung
|
|
ES2119996T3
(es)
|
1992-11-27 |
1998-10-16 |
Napro Biotherapeutics Inc |
Composicion inyectable que comprende faclitaxel.
|
|
JPH0725858A
(ja)
|
1993-07-13 |
1995-01-27 |
Otsuka Pharmaceut Co Ltd |
ピペラジン誘導体
|
|
US5958980A
(en)
|
1993-08-26 |
1999-09-28 |
Glaxo Wellcome, Inc. |
Immunopotentiatory agent and physiologically acceptable salts thereof
|
|
IL110787A0
(en)
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
|
GB9402809D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9402807D0
(en)
|
1994-02-14 |
1994-04-06 |
Xenova Ltd |
Pharmaceutical compounds
|
|
GB9426224D0
(en)
|
1994-12-23 |
1995-02-22 |
Xenova Ltd |
Pharmaceutical compounds
|
|
US5891877A
(en)
|
1995-02-14 |
1999-04-06 |
Xenova Limited |
Pharmaceutical compounds
|
|
US5874443A
(en)
|
1995-10-19 |
1999-02-23 |
Trega Biosciences, Inc. |
Isoquinoline derivatives and isoquinoline combinatorial libraries
|
|
US5886210A
(en)
|
1996-08-22 |
1999-03-23 |
Rohm And Haas Company |
Method for preparing aromatic compounds
|
|
JP3131574B2
(ja)
|
1996-09-04 |
2001-02-05 |
新日本製鐵株式会社 |
新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
|
|
US5939098A
(en)
|
1996-09-19 |
1999-08-17 |
Schering Corporation |
Cancer treatment with temozolomide
|
|
US5922683A
(en)
|
1997-05-29 |
1999-07-13 |
Abbott Laboratories |
Multicyclic erythromycin derivatives
|
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
|
ES2352739T3
(es)
|
1997-11-21 |
2011-02-22 |
Purdue Neuroscience Company |
2-aminoacetamidas sustituidas y el uso de las mismas.
|
|
AP1462A
(en)
|
1998-01-29 |
2005-09-02 |
Aventis Pharma Inc |
Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2- aminoacetamide compound and a cyclyzed compound.
|
|
US7141603B2
(en)
|
1999-02-19 |
2006-11-28 |
The Regents Of The University California |
Antitumor agents
|
|
US6069146A
(en)
|
1998-03-25 |
2000-05-30 |
The Regents Of The University Of California |
Halimide, a cytotoxic marine natural product, and derivatives thereof
|
|
IL137974A0
(en)
|
1998-03-26 |
2001-10-31 |
Shionogi & Co |
Indole derivatives having antiviral activity
|
|
US6509331B1
(en)
|
1998-06-22 |
2003-01-21 |
Elan Pharmaceuticals, Inc. |
Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
|
|
GB9818627D0
(en)
|
1998-08-26 |
1998-10-21 |
Glaxo Group Ltd |
Improvements in dva vaccination
|
|
FR2784988B1
(fr)
|
1998-10-23 |
2002-09-20 |
Adir |
Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US7026322B2
(en)
|
1998-11-12 |
2006-04-11 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
US6358957B1
(en)
|
1998-11-12 |
2002-03-19 |
Nereus Pharmaceuticals, Inc. |
Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
|
|
IL148021A0
(en)
|
1999-08-23 |
2002-09-12 |
Dana Farber Cancer Inst Inc |
Novel b7-4 molecules and uses therefor
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
AU784634B2
(en)
|
1999-11-30 |
2006-05-18 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
|
MXPA02006826A
(es)
|
2000-01-18 |
2004-04-05 |
Nereus Phamraceuticals Inc |
Un inhibidor de division celular y un metodo de produccion del mismo.
|
|
AU2001245823A1
(en)
|
2000-03-17 |
2001-10-03 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
|
DE60137037D1
(de)
|
2000-05-09 |
2009-01-29 |
Angiorx Corp |
Piperazindion-verbindungen
|
|
US6583143B2
(en)
|
2000-12-28 |
2003-06-24 |
Neurocrine Biosciences, Inc. |
CRF receptor antagonists and methods relating thereto
|
|
US20030082140A1
(en)
*
|
2001-08-20 |
2003-05-01 |
Fisher Paul B. |
Combinatorial methods for inducing cancer cell death
|
|
AU2003213673A1
(en)
|
2002-03-01 |
2003-09-16 |
Pintex Pharmaceuticals, Inc. |
Pin1-modulating compounds and methods of use thereof
|
|
NZ535992A
(en)
|
2002-05-17 |
2008-11-28 |
Aventis Pharma Sa |
Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
|
|
US7012100B1
(en)
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
|
US7919497B2
(en)
|
2002-08-02 |
2011-04-05 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
US7935704B2
(en)
|
2003-08-01 |
2011-05-03 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
ATE374767T1
(de)
*
|
2002-08-02 |
2007-10-15 |
Nereus Pharmaceuticals Inc |
Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
|
|
SE0202429D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel Compounds
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
AU2005212399B2
(en)
|
2004-02-04 |
2011-09-22 |
Nereus Pharmaceuticals, Inc. |
Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
|
|
WO2005100364A1
(en)
|
2004-04-19 |
2005-10-27 |
Krka, Tovarna Zdravil, D.D. Novo Mesto |
Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
|
|
DE202004018940U1
(de)
|
2004-12-07 |
2006-04-13 |
Asf Verwaltungs Gmbh |
Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
|
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
EP1926724A1
(en)
|
2005-09-21 |
2008-06-04 |
Nereus Pharmaceuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
CA2637387A1
(en)
|
2006-01-18 |
2007-07-26 |
Simon Goodman |
Specific therapy using integrin ligands for treating cancer
|
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
US8129527B2
(en)
|
2006-11-03 |
2012-03-06 |
Nereus Pharmacuticals, Inc. |
Analogs of dehydrophenylahistins and their therapeutic use
|
|
CA2678353A1
(en)
|
2007-02-15 |
2008-08-21 |
Mannkind Corporation |
A method for enhancing t cell response
|
|
US20080255035A1
(en)
|
2007-04-13 |
2008-10-16 |
Abraxis Bioscience, Inc. |
Sparc and methods of use thereof
|
|
US20090170837A1
(en)
*
|
2007-08-17 |
2009-07-02 |
Thallion Pharmaceuticals Inc. |
Methods for treating ras driven cancer in a subject
|
|
US8569262B2
(en)
|
2007-11-02 |
2013-10-29 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
|
ES2558568T3
(es)
|
2008-01-08 |
2016-02-05 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con agentes moduladores de la tubulina para el tratamiento de enfermedades proliferativas
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
TW202442680A
(zh)
|
2008-12-09 |
2024-11-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
WO2010083434A2
(en)
|
2009-01-16 |
2010-07-22 |
Teva Biopharmaceuticals Usa, Inc. |
New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
|
|
WO2010114922A1
(en)
|
2009-03-31 |
2010-10-07 |
Agios Pharmaceuticals, Inc. |
Methods of treating cancer having an aberrant egfr or kras genotype
|
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
|
ES2543280T3
(es)
|
2009-08-10 |
2015-08-17 |
Board Of Regents, The University Of Texas System |
Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
|
|
CA2774015A1
(en)
|
2009-09-15 |
2011-03-24 |
Cerulean Pharma Inc. |
A cdp-camptothecin conjugate, particle or composition and uses thereof
|
|
EP2490713A2
(en)
|
2009-10-23 |
2012-08-29 |
MannKind Corporation |
Cancer immunotherapy and method of treatment
|
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
|
CN101766815B
(zh)
|
2009-12-31 |
2012-04-25 |
胡松华 |
紫杉醇及多西紫杉醇的用途
|
|
US20130225424A1
(en)
*
|
2010-03-03 |
2013-08-29 |
Targeted Molecular Diagnostics, Llc |
Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
|
|
US20130064831A1
(en)
|
2010-05-17 |
2013-03-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
US20130131018A1
(en)
|
2010-06-04 |
2013-05-23 |
Exonhit S.A. |
Substituted isoquinolines and their use as tubulin polymerization inhibitors
|
|
JP2012033526A
(ja)
|
2010-07-28 |
2012-02-16 |
Fuji Electric Co Ltd |
薄膜太陽電池およびその製造方法
|
|
WO2012035436A1
(en)
*
|
2010-09-15 |
2012-03-22 |
Tokyo University Of Pharmacy And Life Sciences |
Plinabulin prodrug analogs and therapeutic uses thereof
|
|
EP2646577A2
(en)
|
2010-11-29 |
2013-10-09 |
Precision Therapeutics Inc. |
Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
|
|
TWI386203B
(zh)
|
2011-01-07 |
2013-02-21 |
Univ China Medical |
治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
|
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
|
US20140349878A1
(en)
|
2011-11-28 |
2014-11-27 |
National Research Council Of Canada |
Paclitaxel response markers for cancer
|
|
US20150004175A1
(en)
|
2011-12-13 |
2015-01-01 |
Yale University |
Compositions and Methods for Reducing CTL Exhaustion
|
|
CA3122808A1
(en)
|
2012-05-09 |
2013-11-14 |
Cantex Pharmaceuticals, Inc. |
Treatment of myelosuppression
|
|
AU2013204313C1
(en)
|
2012-06-01 |
2016-04-07 |
Bionomics Limited |
Combination Therapy
|
|
WO2014066834A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
|
ES2760023T3
(es)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
|
|
AU2014244083B2
(en)
|
2013-03-13 |
2018-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
WO2014174480A1
(en)
|
2013-04-24 |
2014-10-30 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
|
BR112015028326A8
(pt)
|
2013-06-03 |
2018-01-23 |
Novartis Ag |
combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
|
|
KR102225371B1
(ko)
|
2013-10-11 |
2021-03-10 |
비욘드스프링인크. |
플리나불린 및 탁산의 조합에 의한 암 치료
|
|
EP3065772B1
(en)
|
2013-11-05 |
2024-07-24 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
KR102357699B1
(ko)
|
2013-11-06 |
2022-02-04 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
발현 프로파일링에 의한 림프종 유형의 하위유형 분류 방법
|
|
CN104796448B
(zh)
|
2014-01-22 |
2019-02-12 |
腾讯科技（深圳）有限公司 |
网络系统的数据处理方法和装置
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
RU148945U1
(ru)
|
2014-07-29 |
2014-12-20 |
Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) |
Конвективный блок водогрейного котла
|
|
US10392444B2
(en)
|
2014-08-08 |
2019-08-27 |
Oncoquest, Inc. |
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
|
|
WO2016081281A1
(en)
|
2014-11-17 |
2016-05-26 |
Salk Institute For Biological Studies |
Lipophilic bisphosphonates and methods of use
|
|
NZ734256A
(en)
|
2015-02-12 |
2019-02-22 |
Beyondspring Pharmaceuticals Inc |
Use of plinabulin in combination with immune checkpoint inhibitors
|
|
EP3265091A4
(en)
|
2015-03-06 |
2018-08-01 |
Beyondspring Pharmaceuticals Inc. |
Method of treating a brain tumor
|
|
JP6769982B2
(ja)
|
2015-03-06 |
2020-10-14 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
Ｒａｓ変異と関連するがんの治療方法
|
|
WO2016165007A1
(en)
|
2015-04-17 |
2016-10-20 |
The University Of British Columbia |
Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
|
|
CN106279039B
(zh)
|
2015-06-02 |
2019-01-11 |
青岛海洋生物医药研究院股份有限公司 |
氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
|
|
CN108026075B
(zh)
|
2015-07-13 |
2021-06-29 |
大连万春布林医药有限公司 |
普那布林组合物
|
|
CA2996426A1
(en)
|
2015-10-05 |
2017-04-13 |
Cedars-Sinai Medical Center |
Method of classifying and diagnosing cancer
|
|
RU2753543C1
(ru)
|
2016-02-08 |
2021-08-17 |
Бейондспринг Фармасьютикалс, Инк. |
Композиции, содержащие тукаресол или его аналоги
|
|
EP3463337A4
(en)
|
2016-06-06 |
2020-02-12 |
Beyondspring Pharmaceuticals, Inc. |
COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
|
|
WO2018129381A1
(en)
|
2017-01-06 |
2018-07-12 |
Beyondspring Pharmaceuticals, Inc. |
Tubulin binding compounds and therapeutic use thereof
|
|
SG11201907023UA
(en)
|
2017-02-01 |
2019-08-27 |
Beyondspring Pharmaceuticals Inc |
Method of reducing neutropenia
|
|
DK3595653T3
(da)
|
2017-03-13 |
2023-04-17 |
Beyondspring Pharmaceuticals Inc |
Sammensætninger af plinabulin og anvendelse heraf
|
|
WO2019126739A1
(en)
|
2017-12-21 |
2019-06-27 |
Shepherd Therapeutics, Inc. |
Pyrvinium pamoate anti-cancer therapies
|
|
BR112020014960A2
(pt)
|
2018-01-24 |
2020-12-22 |
Beyondspring Pharmaceuticals, Inc. |
Composição e método para redução de trombocitopenia
|
|
CN112105363A
(zh)
|
2018-02-01 |
2020-12-18 |
大连万春布林医药有限公司 |
用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
|
|
CN110240592A
(zh)
|
2018-03-08 |
2019-09-17 |
青岛海洋生物医药研究院股份有限公司 |
(z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
|
|
CA3095709A1
(en)
|
2018-04-05 |
2019-10-10 |
Noviga Research Ab |
Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
|
|
WO2019232257A1
(en)
|
2018-06-01 |
2019-12-05 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method of treating cancer associated with egfr mutation
|
|
CN112638388A
(zh)
|
2018-08-16 |
2021-04-09 |
大连万春布林医药有限公司 |
刺激免疫反应的方法和组合物
|
|
EP3880848A4
(en)
|
2018-11-14 |
2022-07-27 |
Beyondspring Pharmaceuticals, Inc. |
METHODS OF TREATMENT OF CANCER USING TUBULIN BINDERS
|
|
CN112778155B
(zh)
|
2019-11-11 |
2023-08-11 |
大连万春布林医药有限公司 |
妥卡雷琐衍生物及其用途
|
|
US20230181605A1
(en)
|
2020-05-04 |
2023-06-15 |
Beyondspring Pharmaceuticals, Inc. |
Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
|